Clinical Advisor11h
Tau-Targeting Antisense Therapy for Alzheimer Disease Gets Fast Track Status
BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...
PharmExec1d
FDA Grants Fast Track Designation to Biogen’s Novel Alzheimer Disease Drug Candidate
BIIB080 marks the first antisense oligonucleotide targeting tau to enter clinical development for the treatment of Alzheimer ...
Biogen’s tau targeting Alzheimer’s disease therapy gets FDA Fast Track status
Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...
Biogen announces U.S. FDA granted Fast Track designation to BIIB080
Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to BIIB080, an investigational ...
BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag
The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease ...
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531
Wave Life Sciences Ltd. shares promising updates on AATD & DMD treatments. Click here for my updated look at WVE stock ...
Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease
Biogen on Wednesday said BIIB080 is the first tau-targeting antisense oligonucleotide therapy to enter clinical development for Alzheimer's disease and that it is currently being evaluated in a global ...
Managed Healthcare Executive9h
Caregiver Burden and Value Assessments in Duchenne Muscular Dystrophy
Doing more to incorporate caregiver burden into value assessments and cost-effectiveness research of Duchene muscular dystrophy treatments was the focus of a recent International Society for ...
Labiotech.eu18h
Beyond amyloid: The search for the next big thing in Alzheimer’s treatment
Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.
Fierce Pharma6d
Ionis, Arrowhead, Amarin sponsor new triglyceride group to educate physicians
Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...
Managed Healthcare Executive9d
FDA Grants Priority Review BLA for Spinal Muscular Atrophy Drug, Apitegromab
A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.